Literature DB >> 16368976

Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells.

Christine Roshick1, Heidi Wood, Harlan D Caldwell, Grant McClarty.   

Abstract

Gamma interferon (IFN-gamma)-induced effector mechanisms have potent antichlamydial activities that are critical to host defense. The most prominent and well-studied effectors are indoleamine dioxygenase (IDO) and nitric oxide (NO) synthase. The relative contributions of these mechanisms as inhibitors of chlamydial in vitro growth have been extensively studied using different host cells, induction mechanisms, and chlamydial strains with conflicting results. Here, we have undertaken a comparative analysis of cytokine- and lipopolysaccharide (LPS)-induced IDO and NO using an extensive assortment of human and murine host cells infected with human and murine chlamydial strains. Following cytokine (IFN-gamma or tumor necrosis factor alpha) and/or LPS treatment, the majority of human cell lines induced IDO but failed to produce NO. Conversely, the majority of mouse cell lines studied produced NO, not IDO. Induction of IDO in human cell lines inhibited growth of L2 and mouse pneumonitis agent, now referred to as Chlamydia muridarum MoPn equally in all but two lines, and inhibition was completely reversible by the addition of tryptophan. IFN-gamma treatment of mouse cell lines resulted in substantially greater reduction of L2 than MoPn growth. However, despite elevated NO production by murine cells, blockage of NO synthesis with the l-arginine analogue N-monomethyl-l-arginine only partially rescued chlamydial growth, suggesting the presence of another IFN-gamma-inducible antichlamydial mechanism unique to murine cells. Moreover, NO generated from the chemical nitric oxide donor sodium nitroprusside showed little direct effect on chlamydial infectivity or growth, indicating a natural resistance to NO. Finally, IFN-gamma-inducible IDO expression in human HeLa cells was inhibited following exogenous NO treatment, resulting in a permissive environment for chlamydial growth. In summary, cytokine- and LPS-inducible effectors produced by human and mouse cells differ and, importantly, these host-specific effector responses result in chlamydial strain-specific antimicrobial activities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368976      PMCID: PMC1346650          DOI: 10.1128/IAI.74.1.225-238.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue.

Authors:  A M Hansen; C Driussi; V Turner; O Takikawa; N H Hunt
Journal:  Redox Rep       Date:  2000       Impact factor: 4.412

Review 2.  Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase.

Authors:  G C Brown
Journal:  Biochim Biophys Acta       Date:  2001-03-01

Review 3.  Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.

Authors:  S R Thomas; R Stocker
Journal:  Redox Rep       Date:  1999       Impact factor: 4.412

Review 4.  Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity.

Authors:  C Bogdan; M Röllinghoff; A Diefenbach
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

Review 5.  Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens.

Authors:  C Nathan; M U Shiloh
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

6.  Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice.

Authors:  O Takikawa; Y Tagawa; Y Iwakura; R Yoshida; R J Truscott
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

7.  Molecular basis defining human Chlamydia trachomatis tissue tropism. A possible role for tryptophan synthase.

Authors:  Christine Fehlner-Gardiner; Christine Roshick; John H Carlson; Scott Hughes; Robert J Belland; Harlan D Caldwell; Grant McClarty
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

Review 8.  Role of cytokines in Chlamydia trachomatis protective immunity and immunopathology.

Authors:  Xi Yang
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Indoleamine 2,3-dioxygenase is regulated by IFN-gamma in the mouse placenta during Listeria monocytogenes infection.

Authors:  Ari M Mackler; Ellen M Barber; Osamu Takikawa; Jeffrey W Pollard
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

Review 10.  The role of IFN-gamma in the outcome of chlamydial infection.

Authors:  Martín E Rottenberg; Antonio Gigliotti-Rothfuchs; Hans Wigzell
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

View more
  59 in total

1.  Antigen-Specific CD4+ T Cell-Derived Gamma Interferon Is Both Necessary and Sufficient for Clearing Chlamydia from the Small Intestine but Not the Large Intestine.

Authors:  Hui Lin; Conghui He; John J Koprivsek; Jianlin Chen; Zhiguang Zhou; Bernard Arulanandam; Zhenming Xu; Lingli Tang; Guangming Zhong
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 2.  Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae.

Authors:  Wilhelmina M Huston; Christopher J Barker; Anu Chacko; Peter Timms
Journal:  J Bacteriol       Date:  2014-03-28       Impact factor: 3.490

3.  Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms.

Authors:  Krupakar Jayarapu; Micah Kerr; Susan Ofner; Raymond M Johnson
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

4.  How Chlamydia trachomatis conquered gut microbiome-derived antimicrobial compounds and found a new home in the eye.

Authors:  Arkaprabha Banerjee; David E Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-04       Impact factor: 11.205

5.  Tryptophan Codon-Dependent Transcription in Chlamydia pneumoniae during Gamma Interferon-Mediated Tryptophan Limitation.

Authors:  Scot P Ouellette; Kelsey J Rueden; Elizabeth A Rucks
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

6.  The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cells.

Authors:  Kelsi M Sandoz; William G Valiant; Steven G Eriksen; Dennis E Hruby; Robert D Allen; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  Frameshift mutations in a single novel virulence factor alter the in vivo pathogenicity of Chlamydia trachomatis for the female murine genital tract.

Authors:  Gail L Sturdevant; Laszlo Kari; Donald J Gardner; Norma Olivares-Zavaleta; Linnell B Randall; William M Whitmire; John H Carlson; Morgan M Goheen; Elizabeth M Selleck; Craig Martens; Harlan D Caldwell
Journal:  Infect Immun       Date:  2010-06-14       Impact factor: 3.441

8.  Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract.

Authors:  Gail L Sturdevant; Harlan D Caldwell
Journal:  Pathog Dis       Date:  2014-04-10       Impact factor: 3.166

Review 9.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

10.  Comparable Genital Tract Infection, Pathology, and Immunity in Rhesus Macaques Inoculated with Wild-Type or Plasmid-Deficient Chlamydia trachomatis Serovar D.

Authors:  Yanyan Qu; Lauren C Frazer; Catherine M O'Connell; Alice F Tarantal; Charles W Andrews; Shelby L O'Connor; Ali N Russell; Jeanne E Sullivan; Taylor B Poston; Abbe N Vallejo; Toni Darville
Journal:  Infect Immun       Date:  2015-07-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.